These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 38186863)
1. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. Yin YH; Sang LX; Chang B World J Gastroenterol; 2023 Dec; 29(48):6235-6238. PubMed ID: 38186863 [TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. Patel Chavez C; Cusi K; Kadiyala S J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410 [TBL] [Abstract][Full Text] [Related]
3. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Ranjbar G; Mikhailidis DP; Sahebkar A Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448 [TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
5. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197 [TBL] [Abstract][Full Text] [Related]
6. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS; J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease. Lee HA; Kim HY Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276 [TBL] [Abstract][Full Text] [Related]
8. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Barritt AS; Marshman E; Noureddin M Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164 [TBL] [Abstract][Full Text] [Related]
9. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. Park MJ; Kim H; Kim MG; Kim K Clin Mol Hepatol; 2023 Jul; 29(3):693-704. PubMed ID: 36907574 [TBL] [Abstract][Full Text] [Related]
10. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
11. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Tsiampali C; Papaioannidou P; Goulas A; Polyzos SA Expert Rev Clin Pharmacol; 2023; 16(11):1063-1072. PubMed ID: 37864548 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials. An J; Sohn JH Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018 [TBL] [Abstract][Full Text] [Related]
13. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Sumida Y; Yoneda M; Tokushige K; Kawanaka M; Fujii H; Yoneda M; Imajo K; Takahashi H; Eguchi Y; Ono M; Nozaki Y; Hyogo H; Koseki M; Yoshida Y; Kawaguchi T; Kamada Y; Okanoue T; Nakajima A; Jsg-Nafld JSGON Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168769 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567 [TBL] [Abstract][Full Text] [Related]